Attrition Reducing Technologies (ART)

Accelera is able to offer integrated preclinical profiling platforms called Attrition Reducing Technologies (ART), designed to accelerate the lead optimisation phase. ART allows sponsors to identify the most promising drug candidates at an early stage, while at the same time de-prioritise those with a high risk of failure during the development phase.

ART Assays (*)
  • Solubility and Partitioning
  • Permeability and Transport
  • Chemical stability and Biotransformation
  • Drug-Drug Interaction
  • Safety
  • In Silico models
  • In vivo Testing
(*) for more detailed information, request a copy of  Accelera's ART catalogue